Stay updated with breaking news from Immune Checkpoints. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
– In preclinical studies, CHS-1000 shows a high affinity for human ILT4, reverses ILT4-mediated immunosuppressive functions, leading to activation of immune cells and increased cytokine secretion...
–In preclinical studies, CHS-1000 shows a high affinity for human ILT4, reverses ILT4-mediated immunosuppressive functions, leading to activation of immune cells and increased cytokine secretion–
Onward Therapeutics SA (Onward Therapeutics), a global biotechnology company focused on developing innovative immunotherapies for cancer treatment, today announced that the phase 1 clinical trial of OT-A201 (Study No. A20101), a first-in-class bispecific antibody targeting two immune checkpoints is in progress.
- Interim results from Phase 2 innovaTV 207 trial of tisotumab vedotin in head and neck cancer to be presented -- Initial Phase 1 dose-escalation data for SEA-TGT monotherapy in advanced malignancies to be disclosed -- Preclinical data and discovery research underscore Seagen’s mission to innovate through next-gener...
At the 2023 American Association for Cancer Research (AACR) Regulatory News: OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) (Paris:OSE) today announced it will be presenting five